CClinicalTrials.gg
Status unknownNCT03257397Updated Mar 13, 2019

TBS in Major Depression

An interventional study of theta-burst stimulation (TBS) using a MagPro X1000 and theta-burst stimulation (TBS) using a MagPro X1000 in Treatment Resistant Depression, sponsored by Rupert Lanzenberger. Status unknown at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-13.

Sponsored by Rupert Lanzenberger · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Background Major depression is associated with morbidity and increased mortality. Along with the psychological strain depression represents a high socioeconomic burden costing Europe more than €113 billion/year. About one third of patients do not respond to appropriate therapy. Theta-burst stimulation (TBS), a form of transcranial magnetic stimulation is an emerging treatment for patients for whom pharmacological treatment is ineffective or not appropriate. Based on two different theories of prefrontal dysfunction two TBS-protocols should have the most antidepressant effects. However, no study so far has compared the two approaches or systematically investigated their differential effects on brain function and on a symptom level.

Objectives of the study The aim of this study is to test two TBS protocols on symptom improvement and associated brain function in patients with treatment resistant depression (TRD): iTBS over bilateral DLPFC and iTBS over left and cTBS over right DLPFC. As stimulation over non-motor regions offers no direct readout, fMRI at baseline and after treatment will be harnessed to quantify an effect on brain activity and functional network metrics.

Study population 80 patients with TRD will be enrolled with 40 patients receiving the one, and 40 patients receiving the other TBS protocol for a treatment period of three weeks.

Study design The study is designed as a longitudinal, randomized and double-blind clinical trial. At baseline and after treatment, patients will undergo psychiatric testing using several symptom scales including the Hamilton Depression Rating Scale (HAMD-17), the Beck Depression Inventory (BDI-II), the Inventory of Depressive Symptomatology (IDS-C) and the State-Trait Anxiety Inventory (STAI). Changes in HAMD-17 scores are defined as primary endpoint. Moreover MRI scans before and after treatment will include structural and functional MRI sequences as well as diffusion weighted imaging (DWI) sequence. Functional connectivity and BOLD responses will serve as primary imaging endpoints. A follow-up visit 2 weeks and a final examination 4 weeks after treatment will elucidate durability of effects.

Relevance and implications of the study By investigating which approach is superior for which symptoms our study will contribute to the development of personalized treatment, the reduction of personal suffering and the reduction of costs and occupational disability.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • DSM-5 diagnosis of a single or recurrent major depression
  • Failure of at least two adequate antidepressant treatments
  • HAMD-17 total score of ≥ 23 and a Clinical Global Impression Scale (CGI-S) of ≥ 4
  • Stable psychopharmacological treatment within 2 weeks prior inclusion
  • Age 18-65 years
  • Right-handedness (assessed with the Edinburgh Handedness Inventory)

Exclusion criteria

Exclusion Criteria:

  • Seizures in medical history
  • Medical history of major systemic illness, neurological disorders and previous brain injuries
  • Ferromagnetic implants, cardiac pacemaker, deep brain stimulation and other common MRI and TMS exclusion criteria
  • Current psychotic symptoms
  • Substance abuse or dependence within last 3 months
  • Borderline personality disorder (based on DSM-5 criteria)
  • Pregnancy
  • Active suicidal intent
  • Benzodiazepines other than Lorazepam \< 2mg/d
  • failure to comply with the study protocol or to follow the instructions of the investigating team
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    left iTBS and right cTBS

    40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC

    Device: theta-burst stimulation (TBS) using a MagPro X1000

  • Active comparator
    left and right iTBS

    40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)

    Device: theta-burst stimulation (TBS) using a MagPro X1000

Interventions

  • Devicetheta-burst stimulation (TBS) using a MagPro X1000

    iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions

    Also known as: transcranial magnetic stimulation

  • Devicetheta-burst stimulation (TBS) using a MagPro X1000

    iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions

    Also known as: transcranial magnetic stimulation

05

What researchers measure

Primary outcomes

  1. HAMD

    Hamilton depression rating scale

    Time frame: <1 month

  2. BDI-II

    Beck Depression Inventory

    Time frame: <1 month

Secondary outcomes

  1. Regional white matter microstructure using DWI

    White matter microstructure will be investigated using diffusion tensor imaging and analyzed using tract-based spatial statistics and tractography

    Time frame: <1 month

  2. Regional grey matter volume and using MRI

    Regional grey matter volume will be investigated using voxel-based morphometry

    Time frame: <1 month

Other outcomes

  1. Global physical activity

    assessed using Clinical Global Impression Scale (CGI-S)

    Time frame: <1 month

06

Study locations

1 of 1 sites recruiting
  • Department of Psychiatry and Psychotherapy, Medical University of Vienna
    Vienna, 1090, Austria
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03257397
Lead sponsor
Rupert Lanzenberger
Responsible party
Rupert Lanzenberger (Assoc.-Prof. PD Dr., Medical University of Vienna) — Sponsor-investigator
First posted
Aug 22, 2017
Start date
Aug 1, 2017
Primary completion
Jul 31, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Mar 13, 2019

Study contacts

Georg S Kranz, PhD
Contact
georg.kranz@meduniwien.ac.at
+43 1 40400 ext. 38250
Rupert Lanzenberger, Assoc.Prof
Contact
rupert.lanzenberger@meduniwien.ac.at
+43 1 40400 ext. 35760

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion